Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications.
about
Stable isotope-resolved metabolomics and applications for drug developmentMyc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addictionLinking vitamin B1 with cancer cell metabolismRegulation of the Warburg effect in early-passage breast cancer cells.Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodelingPattern recognition and biomarker validation using quantitative 1H-NMR-based metabolomics.Therapeutic implications of targeting energy metabolism in breast cancer.Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism.Mcl-1 downregulation leads to the heightened sensitivity exhibited by BCR-ABL positive ALL to induction of energy and ER-stress.Inhibition of transketolase by oxythiamine altered dynamics of protein signals in pancreatic cancer cellsUse of the 1-mm micro-probe for metabolic analysis on small volume biological samples.Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study.Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells.Clinical applications of metabolomics in oncology: a review.Use of nuclear magnetic resonance-based metabolomics in detecting drug resistance in cancerMetabolic characteristics of imatinib resistance in chronic myeloid leukaemia cellsPreclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.MR evaluation of response to targeted treatment in cancer cells.MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer.Structural homologies between phenformin, lipitor and gleevec aim the same metabolic oncotarget in leukemia and melanoma.Computational Model Predicts the Effects of Targeting Cellular Metabolism in Pancreatic Cancer.The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines.Exploring cancer metabolism using stable isotope-resolved metabolomics (SIRM).Metabolic assessment of a novel chronic myelogenous leukemic cell line and an imatinib resistant subline by H NMR spectroscopy.ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition.
P2860
Q24629149-2EB1814F-30FB-42C5-A905-1BB2EA31F477Q29616653-CE77CA94-48F4-47A6-9CEF-5B47B04615A9Q34258898-2D2C29C4-4E69-4880-B731-C8D55C3D21DBQ34594985-8039B323-2614-4C69-ABF0-00F92DE907D9Q36228895-B0F9E541-42D7-45FC-A338-EBAE06C77F13Q36607286-DA9AD933-36D4-4DEE-9504-8BBCDBB37541Q36619161-33C0B672-23B6-4A93-A2DD-0B07FB426235Q36630017-BE44CC29-385D-456B-B70F-FBD906D715A7Q36665287-17E3AC81-A1D7-43FF-9661-F1D76F8F0F67Q37071513-92506CAC-037A-4A70-BA4C-25D1A55E12A1Q37084838-0A2DA4EF-5911-4633-8DCE-6C88E862784DQ37141914-4D846AC0-ED3A-4AF5-8EAA-016C7E77ACE2Q37161696-DCEAE3C4-9CEC-4DD4-9CD1-56DB204EEC8EQ37177549-59CB53BA-0658-4321-B57A-223E9A9751B2Q37374479-787AA35B-0E47-4918-90E6-52DCD8BF316EQ37376981-0AD705D2-01F5-4FF9-BAFA-A0E9455B9378Q37421431-8DB4C615-F72D-42DA-BFC5-65DD6F39408FQ37851076-A7AA6303-C4D2-4521-B58B-B777E6CFBAB7Q37906482-EA541F0C-9778-4926-9F37-8C2E9A2138EAQ38707129-3765D873-236A-4D58-BD2A-92D166BC3DF4Q38817911-FBB36896-9CBB-4FE5-825F-7BEF684B728BQ39202160-D44B4F77-A139-49DA-B141-4CAE3D597806Q39358317-51D9D016-6957-4340-9232-B03319111182Q39672888-21518117-81FE-473D-B25E-282ABB23E29CQ42081830-ED2CA108-9AAA-48AC-9E17-2363BCBBB342
P2860
Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Detection of resistance to ima ...... drug development implications.
@ast
Detection of resistance to ima ...... drug development implications.
@en
Detection of resistance to ima ...... drug development implications.
@nl
type
label
Detection of resistance to ima ...... drug development implications.
@ast
Detection of resistance to ima ...... drug development implications.
@en
Detection of resistance to ima ...... drug development implications.
@nl
prefLabel
Detection of resistance to ima ...... drug development implications.
@ast
Detection of resistance to ima ...... drug development implications.
@en
Detection of resistance to ima ...... drug development implications.
@nl
P1476
Detection of resistance to ima ...... drug development implications.
@en
P2093
László G Boros
Natalie Serkova
P304
P356
10.2165/00129785-200505050-00002
P577
2005-01-01T00:00:00Z
P5875
P6179
1014596025